{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:25:06Z","timestamp":1778624706233,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ctrv.2014.06.005","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T01:30:41Z","timestamp":1403141441000},"page":"927-933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Systematic review of combination therapies for mycosis fungoides"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniel","family":"Humme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staffan","family":"Vandersee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctrv.2014.06.005_b0005","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.06.005_b0010","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2014.06.005_b0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ddg.12015_5","article-title":"Brief S2k guidelines \u2013 cutaneous lymphomas","volume":"11","author":"Stadler","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2014.06.005_b0020","doi-asserted-by":"crossref","first-page":"ii72","DOI":"10.1093\/annonc\/mdn095","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dummer","year":"2008","journal-title":"Ann Oncol"},{"issue":"8 Suppl.","key":"10.1016\/j.ctrv.2014.06.005_b0025","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000248098","article-title":"Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a","volume":"179","author":"Nicolas","year":"1989","journal-title":"Dermatologica"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0370","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Association of Dermatologists, U.K. Cutaneous Lymphoma Group, Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1346-8138.2012.01639.x","article-title":"Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society \u2013 Lymphoma Study Group","volume":"40","author":"Sugaya","year":"2013","journal-title":"J Dermatol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.06.005_b0045","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2014.06.005_b0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000056361","article-title":"Retinoids\u2013which dermatological indications will benefit in the near future?","volume":"14","author":"Zouboulis","year":"2001","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.06.005_b0055","first-page":"514","article-title":"Bexarotene ligand pharmaceuticals","volume":"1","author":"Hurst","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.ctrv.2014.06.005_b0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00280-009-1140-4","article-title":"Bexarotene: a promising anticancer agent","volume":"65","author":"Qu","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1365-2133.2012.10896.x","article-title":"Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas","volume":"166","author":"Terhorst","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2 Suppl. 1","key":"10.1016\/j.ctrv.2014.06.005_b0070","first-page":"33","article-title":"Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies","volume":"21","author":"Duvic","year":"2007","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.ctrv.2014.06.005_b0075","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.06.005_b0080","unstructured":"OCEBM Levels of Evidence Working Group\u2217. \u201cThe Oxford Levels of Evidence 2\u201d. Oxford Centre for Evidence-Based Medicine. <http:\/\/www.cebm.net\/index.aspx?o=5653>."},{"issue":"10","key":"10.1016\/j.ctrv.2014.06.005_b0085","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"issue":"6 Suppl.","key":"10.1016\/j.ctrv.2014.06.005_b0090","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1468-3083.2010.03732.x","article-title":"PUVA plus interferon a\u03b1-2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series","volume":"25","author":"Nikolaou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.06.005_b0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-alpha-2a plus psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.06.005_b0110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-3-642-78771-3_30","article-title":"Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy","volume":"139","author":"Stadler","year":"1995","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-3083.2011.04011.x","article-title":"Comparison of pegylated interferon \u03b1-2b plus psoralen PUVA versus standard interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma","volume":"26","author":"H\u00fcsken","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0120","first-page":"1185","article-title":"PUVA vs PUVA and interferon alpha for treatment of mycosis fungoides","volume":"121","author":"Kujawska","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0125","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archderm.1993.01680270085011","article-title":"Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA","volume":"129","author":"Mostow","year":"1993","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2008.08886.x","article-title":"Psoralen plus ultraviolet A +\/\u2212 interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways","volume":"160","author":"Wozniak","year":"2009","journal-title":"Br J Dermatol"},{"issue":"18S","key":"10.1016\/j.ctrv.2014.06.005_b0135","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/jco.2006.24.18_suppl.7541","article-title":"Prospective, randomized, multicentre clinical trial on the use of interferon a2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II","volume":"24","author":"Stadler","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.06.005_b0140","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"suppl. 3","key":"10.1016\/j.ctrv.2014.06.005_b0145","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA)compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00128071-200809030-00005","article-title":"Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides","volume":"9","author":"Papadavid","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0155","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ctrv.2014.06.005_b0160","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000418097","article-title":"Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas","volume":"19","author":"Serri","year":"1990","journal-title":"Curr Probl Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0165","first-page":"573","article-title":"Combination treatment in CTCL: the current role of bexarotene","volume":"147","author":"Delfino","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.06.005_b0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-4362.1993.tb01458.x","article-title":"Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides","volume":"32","author":"Altomare","year":"1993","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.ctrv.2014.06.005_b0175","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate","volume":"125","author":"Dr\u00e9no","year":"1991","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0180","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.1988.tb02600.x","article-title":"Treatment of mycosis fungoides with recombinant interferon-alpha 2a alone and in combination with etretinate","volume":"118","author":"Thestrup-Pedersen","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2014.06.005_b0185","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0190","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/cbr.2007.0402","article-title":"Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides\/S\u00e9zary syndrome","volume":"22","author":"Avil\u00e9s","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1016\/j.ctrv.2014.06.005_b0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mjd.2001.110645","article-title":"Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial","volume":"44","author":"Wollina","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.06.005_b0200","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2014.06.005_b0205","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.06.005_b0210","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630802562427","article-title":"Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma","volume":"20","author":"Kannangara","year":"2009","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"10.1016\/j.ctrv.2014.06.005_b0220","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.06.005_b0225","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/bjc.2013.616","article-title":"Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma","volume":"109","author":"Illidge","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2340\/00015555595963","article-title":"Tumour stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian mycosis fungoides study group","volume":"59","author":"Groth","year":"1979","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0235","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archderm.1995.01690150071014","article-title":"Treatment of advanced mycosis fungoides and S\u00e9zary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue","volume":"131","author":"Schappell","year":"1995","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11864-004-0012-8","article-title":"Therapy for mycosis fungoides","volume":"5","author":"Lundin","year":"2004","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0245","first-page":"395","article-title":"The treatment of mycosis fungoides","volume":"143","author":"Mestel","year":"2008","journal-title":"G Ital Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11532190-000000000-00000","article-title":"Current and emerging treatment strategies for cutaneous T-cell lymphoma","volume":"70","author":"Lansigan","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2014.06.005_b0255","first-page":"CD008946","article-title":"Interventions for mycosis fungoides","volume":"9","author":"Weberschock","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ctrv.2014.06.005_b0260","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ctrv.2014.06.005_b0265","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0270","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2014.06.005_b0275","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2010.05.007","article-title":"Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination","volume":"64","author":"Searles","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.06.005_b0280","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1396-0296.2003.01648.x","article-title":"Systemic chemotherapy for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"16","author":"Kuzel","year":"2003","journal-title":"Dermatol Ther"},{"issue":"26","key":"10.1016\/j.ctrv.2014.06.005_b0285","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2014.06.005_b0290","first-page":"647","article-title":"Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study","volume":"63","author":"Grozea","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"7","key":"10.1016\/j.ctrv.2014.06.005_b0295","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00007611-197607000-00038","article-title":"Combined chemotherapy (COP) in treatment of mycosis fungoides: report of four cases","volume":"69","author":"Leavell","year":"1976","journal-title":"South Med J"},{"issue":"2","key":"10.1016\/j.ctrv.2014.06.005_b0300","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2340\/0001555565179183","article-title":"Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients","volume":"65","author":"Sentis","year":"1985","journal-title":"Acta Derm Venereol"},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2014.06.005_b0305","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428199809057618","article-title":"Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP","volume":"31","author":"Fierro","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.ctrv.2014.06.005_b0310","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000421-198410000-00012","article-title":"Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone","volume":"7","author":"Case","year":"1984","journal-title":"Am J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2014.06.005_b0315","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2133.2005.06682.x","article-title":"Pegylated liposomal doxorubicin in stage IVB mycosis fungoides","volume":"153","author":"Di Lorenzo","year":"2005","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0325","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.06.005_b0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"10.1016\/j.ctrv.2014.06.005_b0335","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ctrv.2014.06.005_b0340","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2014.06.005_b0345","first-page":"655","article-title":"Skin directed therapy for mycosis fungoides: a review","volume":"7","author":"Berthelot","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.ctrv.2014.06.005_b0350","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2014.06.005_b0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ijc.2910390704","article-title":"Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas","volume":"1","author":"Bunn","year":"1987","journal-title":"Int J Cancer Suppl"},{"issue":"3","key":"10.1016\/j.ctrv.2014.06.005_b0360","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and S\u00e9zary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.06.005_b0365","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T21:36:48Z","timestamp":1716845808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0305737214001157"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.06.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of combination therapies for mycosis fungoides","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}